Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Lonza Group    LONN   CH0013841017

LONZA GROUP

(LONN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Lonza : Previews its Newest Clean Label Innovation – Vcaps ® Plus White Opal™, a Titanium Dioxide-Free Capsule

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/06/2019 | 08:13am EDT

Lonza today announces that its new Vcaps® Plus White Opal capsule, which is designed to address the growing demand for opaque capsules that do not include titanium dioxide, is coming soon to the market. By using an alternative opacifier, this new clean label capsule offers a natural semi-opaque look that masks unattractive food supplement ingredients. The new Vcaps® Plus White Opal™ capsule will be presented next week at Vitafoods Europe 2019 in Geneva (CH), where Lonza is the Official Capsule Sponsor.

Demand for a Titanium Dioxide Alternative

Food-grade titanium dioxide, also known as E 171, is a common white pigment that has a long history of use in food supplement applications for its brightness and opacifying properties. However, recent scientific studies indicated potential risks associated with the presence of nanoparticles. Although the data is not conclusive and further research is needed, these findings question the justified use of nanoparticle titanium dioxide as a food additive. With strong ongoing public debate, the marketing of titanium dioxide-containing foodstuffs will be suspended in France beginning January 1, 2020.

As consumer awareness increases, supplement producers are seeking more natural alternatives that are free from titanium dioxide. Lonza's new Vcaps® Plus White Opal capsule, the latest addition to its Capsugel® range of clean label plant-based capsules, is an ideal solution for supplement manufacturers.

Joachim Meier, Director, Head of Sales EMEA, Lonza Consumer Health & Nutrition, commented: 'With four out of five supplement users citing 'unquestionable safety' as a key decision-making factor when purchasing supplements, Lonza has developed the Vcaps® Plus White Opal™ capsule as a high-quality, cutting-edge solution that meets evolving consumer preferences.

As a pioneer in vegetarian capsules with expertise in R&D, scale-up and the regulatory landscape, Lonza can help support supplement manufacturers in the development of innovative products with clean label benefits.'

Time for Color

Lonza will also be showcasing its expanding portfolio of clean label food colored capsules at Vitafoods, including the Vcaps® Plus Blue Spirulina and Purple Carrot capsules and the soon-to-be launched Red Radish and Spicy Yellow. These next-generation capsules enable supplement brands to create vibrant products with colorful appeal, while also maintaining a natural appearance and delivering improved supply chain transparency.

Lonza is the Official Capsule Sponsor of Vitafoods Europe 2019. Lonza will be at booth G10, from 7-9 May, where attendees can talk to the experts or more information is available on www.capsugel.com

Disclaimer

Lonza Group Ltd. published this content on 06 May 2019 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 06 May 2019 12:12:06 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on LONZA GROUP
10/18MESOBLAST : and Lonza Enter GVHD Commercial Manufacturing Agreement
AQ
10/17LONZA : Strengthens Sports Nutrition Portfolio with the Launch of Vegan MuscleGu..
AQ
10/17MESOBLAST : and Lonza Enter into Agreement for Commercial Manufacture of Mesobla..
AQ
10/17GLOBAL MARKETS LIVE : Nestlé, Netflix, Huawei, General Motors…
10/16LONZA : Mesoblast and Lonza Enter Into Agreement for Commercial Manufacture of M..
AQ
10/15GENMAB : Lonza's Ibex Solutions to Support Genmab's Growing Clinical Portfolio
AQ
10/08PREVAIL THERAPEUTICS : and Lonza Establish Strategic Collaboration to Develop an..
AQ
10/08TRACKINSIGHT : Performance boost from Swiss Stocks
TI
10/04LONZA : MODA-ES TM Platform helps Nephron Pharmaceuticals move from paper to an ..
AQ
10/02CELLECTIS : and Lonza Enter cGMP Manufacturing Service Agreement for Cellectis :..
AQ
More news
Financials (CHF)
Sales 2019 5 908 M
EBIT 2019 1 209 M
Net income 2019 736 M
Debt 2019 3 244 M
Yield 2019 0,85%
P/E ratio 2019 34,1x
P/E ratio 2020 28,6x
EV / Sales2019 4,77x
EV / Sales2020 4,41x
Capitalization 24 917 M
Chart LONZA GROUP
Duration : Period :
Lonza Group Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LONZA GROUP
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 373,42  CHF
Last Close Price 335,60  CHF
Spread / Highest target 37,7%
Spread / Average Target 11,3%
Spread / Lowest Target -18,1%
EPS Revisions
Managers
NameTitle
Marc Funk Chief Executive Officer
Albert M. Baehny Chairman
Rodolfo Savitzky Chief Financial Officer
Patrick Aebischer Vice Chairman
Margot A. Scheltema Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
LONZA GROUP32.98%25 271
IQVIA HOLDINGS INC.23.52%28 109
CELLTRION, INC.--.--%19 657
INCYTE CORPORATION22.28%16 724
SEATTLE GENETICS, INC.54.25%14 852
EXACT SCIENCES CORPORATION52.88%12 491